Xenetic Biosciences Announces $4.5 Million Stock Offering

Xenetic Biosciences, Inc. (NASDAQ: XBIO), a biopharmaceutical company specializing in immuno-oncology technologies, has announced a new public offering. This offering comprises 735,000 shares of common stock priced at $6.12 per share, totaling approximately $4.5 million in gross proceeds. The transaction is set to close around October 14, 2025, pending standard closing conditions.

Canaccord Genuity is serving as the sole bookrunner for this offering. The proceeds are earmarked for general corporate purposes and working capital. The offering is being executed under a shelf registration statement filed with the SEC. This announcement is not a solicitation or offer for sale in jurisdictions where such would be unlawful.